Global Antimycotic Drugs Market, By Drug Type (Azoles, Polyenes, Allylamines), Treatment (Amphotericin B, Antifungal Therapy for Invasive and Serious Mycoses), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Antimycotic Drugs Market Analysis and Size
The antimycotic drugs market is anticipated to witness substantial growth during the forecast period. Mycoses are caused by certain fungi, yeasts, molds and some fungi which can exist both as a mould and yeast. The fungal infection causes candidiasis, fungal pneumonia, mucormycosis, and other diseases. The antifungal drugs market is constantly increasing and developing because of the robust developmental efforts made by researchers and market players in the field.
Data Bridge Market Research analyses a growth rate in the antimycotic drugs market in the forecast period 2023-2030. The expected CAGR of antimycotic drugs market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 15.3 billion in 2022, and it would grow upto USD 20.94 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Antimycotic Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Type (Azoles, Polyenes, Allylamines, Quinazoles), Treatment (Amphotericin B, Antifungal Therapy for Invasive and Serious Mycoses), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Endo International Inc (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland.), Pfizer Inc (U.S.), Lupin (India), Vintage Labs (India), Abbvie Inc. (U.S.), Zydus Group (India), Wockhardt (India), Lannett (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Antimycotic medication, also known as antifungal medication, is a kind of pharmaceutical fungicide or fungi static that is used to treat mycosis, fungi, and other infections. Mycosis is a disease caused by fungus which invades healthy tissue, gets confined to skin, and spreads into tissue and organs or affects the whole body. Patients with early-stage mycosis may survive for many years.
Global Antimycotic Drugs Market Dynamics
Drivers
- Increase in Fungal Infections
Fungal diseases are a growing public health crisis. People with weak immunity has more chances to infected with fungal infection. There is a growing possibility of the development of fungal infections in patients suffering from AIDS. According to the statistics published by the Centers for Disease Control and Prevention in 2016, around 220,000 new individuals are affected by cryptococcal meningitis and has resulted in 181,000 deaths per year round the world. This boosts the market growth.
- Increasing Demand of OTC Drugs
Increasing the number of over-the-counter antiretroviral (OTC) drugs in developing countries is enhancing the market growth. With the rising popularity of over-the-counter (OTC) drugs such as clotrimazole, ketoconazole, miconazole, econazole, and amorolfine, numerous patients are found to be taking OTC drugs to obtain a prescription from a health professional. These drugs are found to be very helpful in the treatment of fungal infections.
Opportunities
- Higher Public-Private Partnerships
There are higher partnerships between major market players and organizations developing with each passing decade. The current public-private partnership agreements in the pharmaceutical industry for the huge development of novel medications are estimated to offer huge growth opportunities to the market for mycoses drugs. For instance, CARB-X, an international public-private partnership, is expected to provide around USD 350 million in the coming five years to increase the R&D pipeline. Partners involved are Antimicrobial Resistance Centre in England, the U.S. Department of Health and Human Services, and Boston University School of Law.
- Increasing Demand for Azoles
The higher demand for azoles can be attributed to the growth of the market. These agents support fungistatic activities by hindering fungal enzymes. Azoles are used in the treatment of candidemia, systemic candidiasis, blastomycosis, and ocular fungal infections. It is also used in the treatment of systemic fungal infections. They offer a widespread spectrum of activity and improved safety levels. Triazoles have fewer adverse effects, less severe drug interactions, and improved absorption and distribution properties. Thus, it boosts the growth of the market.
Restraints/Challenges
- Increasing Resistance to Antifungal Drugss
Resistance can also develop over the period of when fungi when the patient is exposed to antifungal drugs. This resistance can occur when antifungal drugs are used to treat sick people, particularly if the drugs are used improperly, for instance, when dosages are too low or when treatment courses are not long enough.
- Side effects of Antimycotic Drugs
There are various side effects that are associated with hampering the market growth. Effects such as itching or burning, redness, abdominal pain, rash hamper the market growth.
This antimycotic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the antimycotic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Antimycotic Drugs Market
Over the period of 2020 and 2021, the COVID-19 pandemic had a major impact on most of the medical procedures. People were limited from visiting hospitals for numerous medical treatments and procedures due to COVID-19 pandemic restrictions. The antimycotic drugs range also saw a decline in demand, as the focus was mainly on COVID-19. Moreover, there was a shortage of the equipment, drugs, and materials required to complete successful antimycotic drug procedures. Though, the global antimycotic drugs market is again regaining its growth with the upliftment of everything and also the shift towards different other diseases.
Recent Development
- In 2019, Mayne Pharma announced the launch of the TOLSURA 65mg capsule in the U.S.. TOLSURA is a formulation of itraconazole which has been shown to treat fungal infections of the system, which includes blastomycosis, histoplasmosis, aspergillosis, and others.
Global Antimycotic Drugs Market Scope
The antimycotic drugs market is segmented on the basis of drug type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Type
- Azoles
- Itraconazole
- Fluconazole
- Polyenes
- Nystatin
- Amphotericin b
- Allylamines
- Dermatophyte
- Naftifine
- Others
Treatment
- Amphotericin B
- Antifungal Therapy for Invasive and Serious Mycoses
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Antimycotic Drugs Market Regional Analysis/Insights
The antimycotic drugs market is analyzed and market size insights and trends are provided by drug type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the antimycotic drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing positive growth for antimycotic drugs market throughout the forecasted period due to the presence of primary manufacturers, extensive spending on R&D and health care and qualified professionals.
Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturers and increase in government initiatives.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Antimycotic Drugs Market Share Analysis
The antimycotic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to antimycotic drugs market.
Key players operating in the antimycotic drugs market include:
- Novartis AG (Switzerland)
- Endo International Inc (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Lupin (India)
- Vintage Labs (India
- Abbvie Inc. (U.S.)
- Zydus Group (India)
- Wockhardt (India)
- Lannett (U.S.)
SKU-